UNIVERSITY OF UTAH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1850-02-28
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.utah.edu
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
Phase 2
Completed
- Conditions
- Prostate Cancer Metastatic to Bone
- Interventions
- Radiation: Radiation
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 20
- Registration Number
- NCT03304418
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
Phase 2
Terminated
- Conditions
- IDH1 Gene MutationPlasma Cell MyelomaSecondary MyelofibrosisASXL1 Gene MutationEZH2 Gene MutationPrimary MyelofibrosisAnemiaIDH2 Gene MutationRecurrent Plasma Cell MyelomaThrombocytopenia
- Interventions
- Procedure: Hematopoietic Cell TransplantationOther: Laboratory Biomarker Analysis
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 6
- Registration Number
- NCT03303950
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Behavioral Interventions for Chronic Pain and Opioid-Related Problems
Not Applicable
Completed
- Conditions
- Chronic Pain
- Interventions
- Behavioral: Mindfulness-Oriented Recovery EnhancementBehavioral: Supportive Counseling
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 95
- Registration Number
- NCT03298269
- Locations
- 🇺🇸
College of Social Work, Salt Lake City, Utah, United States
Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)
Phase 1
Completed
- Conditions
- Ocular Graft Versus Host Disease
- Interventions
- Other: Saline SolutionBiological: Amniotic Fluid Eye Drops (AFED)
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 15
- Registration Number
- NCT03298815
- Locations
- 🇺🇸
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States
Merestinib on Bone Metastases in Subjects With Breast Cancer
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 2
- Registration Number
- NCT03292536
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
Phase 1
Terminated
- Conditions
- Brain Tumor
- Interventions
- Drug: [18F]FLTDrug: [18F]Fluciclovine
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 10
- Registration Number
- NCT03276676
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 7
- Registration Number
- NCT03259425
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
The Development of a Cognitive Reassurance Training Program
Not Applicable
Terminated
- Conditions
- Low Back Pain
- Interventions
- Other: Cognitive reassurance training
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 128
- Registration Number
- NCT03256617
- Locations
- 🇺🇸
University of Utah Health Care Out Patient Physical Therapy Clinics, Salt Lake City, Utah, United States
Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
Phase 2
Completed
- Conditions
- Venous ThromboembolismDeep Venous ThrombosisSurgery
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 131
- Registration Number
- NCT03251963
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Hyperhidrosis in Patients With Amputations-Botox
Phase 1
Completed
- Conditions
- Hyperhidrosis
- Interventions
- Drug: Botulinum Toxin Type A (Botox)
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 25
- Registration Number
- NCT03236012
- Locations
- 🇺🇸
University of Utah Hospital, Salt Lake City, Utah, United States
🇺🇸George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, United States